Titan Pharmaceuticals Stock Today
| TTNP Stock | USD 3.78 0.08 2.07% |
Performance0 of 100
| Odds Of DistressOver 86
|
Titan Pharmaceuticals is selling at 3.78 as of the 1st of December 2024; that is 2.07 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 3.76. Titan Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Titan Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of January 1996 | Category Healthcare | Classification Health Care |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. The company was incorporated in 1992 and is based in South San Francisco, California. Titan Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 914.23 K outstanding shares of which 8.71 K shares are at this time shorted by private and institutional investors with about 1.04 trading days to cover. More on Titan Pharmaceuticals
Moving together with Titan Stock
| 0.82 | HLN | Haleon plc | PairCorr |
| 0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.71 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.85 | ANRO | Alto Neuroscience, | PairCorr |
| 0.79 | SHG | Shinhan Financial | PairCorr |
Moving against Titan Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Titan Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Board | Gim Seow | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTitan Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Titan Pharmaceuticals' financial leverage. It provides some insight into what part of Titan Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Titan Pharmaceuticals (TTNP) is traded on NASDAQ Exchange in USA. It is located in 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 4 people. Titan Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.34 M. Titan Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 914.23 K outstanding shares of which 8.71 K shares are at this time shorted by private and institutional investors with about 1.04 trading days to cover.
Titan Pharmaceuticals currently holds about 6.42 M in cash with (7.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Titan Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationTitan Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Titan Ownership Details
Titan Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| St Germain D J Co Inc | 2024-09-30 | 1.0 | |
| Westside Investment Management, Inc. | 2024-06-30 | 1.0 | |
| Ubs Group Ag | 2024-06-30 | 1.0 | |
| Cape Investment Advisory, Inc. | 2024-06-30 | 1.0 | |
| Fmr Inc | 2024-09-30 | 0.0 | |
| Bb&t Corp. | 2024-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 11.1 K | |
| Tower Research Capital Llc | 2024-06-30 | 717 | |
| Mcf Advisors, Llc | 2024-06-30 | 165 | |
| Bank Of America Corp | 2024-06-30 | 17.0 | |
| Group One Trading, Lp | 2024-06-30 | 12.0 |
Titan Pharmaceuticals Historical Income Statement
Titan Stock Against Markets
Titan Pharmaceuticals Corporate Management
| Brian Crowley | Senior Administration | Profile | |
| Joe Schrei | Executive Operations | Profile | |
| Marc MD | Ex Director | Profile | |
| David Lazar | Principal Officer | Profile |
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.